Objectives: The Manchester Acute Coronary Syndromes (MACS) decision aid can 'rules in' and 'rule out' acute coronary syndromes (ACS) by combining a patient's symptoms with the results of a single blood test taken at the time of arrival in the Emergency Department (ED). The original model (MACS) included two biomarkers: high sensitivity cardiac troponin T (hs-cTnT) and heart-type fatty acid binding protein (h-FABP). A refined model without h-FABP was found to have comparable sensitivity but greater specificity. We sought to validate MACS and T-MACS using the contemporary Siemens Advia Centaur cardiac troponin I assay to increase usability in practice. Methods: This is a secondary analysis from prospective diagnostic cohort study at Stepping Hill Hospital, United Kingdom. Patients presenting with chest pain of suspected cardiac nature warranting rule out for ACS were included. All patients underwent hs-cTnT testing at least 12 h after peak symptoms. The primary outcome was a diagnosis of ACS, defined as either prevalent acute myocardial infarction (AMI) or incident major adverse cardiac events (death, AMI or coronary revascularization) within 30 days. Results: Of 405 included patients, 76 (18.8%) had ACS. MACS and T-MACS had similar C-statistics (0.94 for each, p = 0.36) and sensitivity (difference 1.3%, 95% CI −1.3 to 3.9%, p = 1.00) but T-MACS had significantly greater specificity (difference 16.7%, 95% CI 14.6-18.9%, p b 0.0001). T-MACS and MACS would have allowed 36.3% and 22.5% patients to be immediately discharged respectively. Of patients classified as 'very low risk', none had ACS when MACS was used compared to one (0.7%) with T-MACS. Conclusion: Both MACS and T-MACS effectively ruled out ACS even with a contemporary troponin I assay and could be used to reduce unnecessary hospital admissions.
Background
Patients presenting with chest pain to the emergency department (ED) are the group most commonly requiring emergency hospital admission [1] . Serial troponin testing for rule out of acute coronary syndromes (ACS) remains the standard of care with the latest high sensitivity troponin assays still lacking sufficient diagnostic sensitivity to rule out ACS with a single blood test on arrival to the ED using conventional diagnostic thresholds [2, 3] .
The Manchester Acute Coronary Syndromes (MACS) decision aid is a prospectively validated rule out and risk stratification strategy for ACS based on a single blood test on arrival in patients presenting with suspected cardiac chest pain to the ED. The computer based MACS model consists of a combination of five patient symptoms (worsening angina, vomiting, observed diaphoresis, pain radiating to the right arm and hypotension with a systolic blood pressure b 100 mm Hg), ischaemia on the ECG and two biomarker concentrations: high sensitivity cardiac troponin T (hs-cTnT) and heart-type fatty acid binding protein (h-FABP) [4] . As h-FABP is not commonly used in practice, its inclusion was considered by some to be a barrier to clinical implementation. We therefore recently derived and validated the refined T-MACS model in which hs-cTnT is the only biomarker [5] .
Both models predicted major adverse cardiac events (MACE) at 30 days at 97.9%, 98.2% and 100% sensitivity for MACS and 96.3% and 98.1% sensitivity for T-MACS in the respective (external) validation studies [5] [6] [7] [8] [9] . One limitation of the (T-)MACS rule is that has only been validated with the Roche Diagnostics Elecsys hs-cTnT assay to date.
American Journal of Emergency Medicine 36 (2018) [602] [603] [604] [605] [606] [607] High sensitivity cardiac troponin assays are not uniformly available at all hospitals. This highlights a pressing need to validate the MACS rule with contemporary cardiac troponin assays that do not meet criteria for being labelled as 'high sensitivity' [10] . One of the more commonly used contemporary assays is the cardiac troponin I Ultra assay manufactured by Siemens (cTnI; Siemens ADVIA Centaur).
We sought to validate the MACS and T-MACS rule for the Siemens Advia Centaur cTnI assay. In doing so, we aimed to evaluate the diagnostic accuracy of both the original MACS rule and the refined T-MACS model.
Methods

Design and setting
This work shows a secondary analysis of data collected in a prospective diagnostic cohort study conducted between April and July 2010 in the ED of Stepping Hill Hospital, Stockport, United Kingdom, a district general hospital with approximately 80,000 patients annually attending the ED.
The Research Ethics Committee granted ethical approval (reference 09/H1014/74) and all participants provided written informed consent. We have published several separate analyses from this study [4, 6, 11, 12] .
Study participants
Patients aged N 25 years presenting to the ED with chest pain which the treating physician suspects to be cardiac in nature, warranting investigations to rule out ACS were included if peak symptom onset was reported within the last 24 h. Patients were asked to provide initial verbal consent to the treating ED physician at the time of their initial presentation to the ED. Written informed consent was later sought by a member of the research team approaching the patient either in hospital or requesting written informed consent by post. If patients were unable to provide written informed consent they were not eligible for inclusion in the study.
We excluded patients if they required hospital admission for another medical condition, needed dialysis due to renal failure, presented with significant chest trauma suspicious for myocardial contusion, were pregnant, did not speak English, were prisoners and those for whom follow up would be impossible by any means.
Data collection and laboratory analysis
All clinical data was prospectively collected by the initial treating ED physician using a custom-designed case report form documenting absence and presence of relevant symptoms and findings on physical examination, ECG interpretation, ED diagnosis, disposition from the ED, as well as patient characteristics including past medical history and current medication use.
Serum blood samples were routinely taken on arrival and at least 12 h after peak symptom onset in all patients presenting with suspected cardiac chest pain to the ED. The serum samples were stored at ≤−70°C and further analysed in subsequently thawed batches for hs-cTnT (Roche Diagnostics Elecsys, 5th generation, 99th percentile 14 ng/L, coefficient of variation b 10% at 13 ng/L), cTnI (Siemens troponin I Ultra, ADVIA Centaur, 99th percentile 40 ng/L, coefficient of variation b 10% at 30 ng/L) and H-FABP (Randox Laboratories, County Antrim, Northern Ireland, automated immunoturbidimetric assay, 99th percentile 6.32 ng/mL, total coefficient of variation 6.85% at 5.47 ng/mL and an assay range from 0.747 to 120 ng/mL). In this report we have only included reference to hs-cTnT measurements from samples that were re-tested using a batch of reagents unaffected by a calibration shift noted by the manufacturer [13] . Subsequent results reported are from the analysis with the unaffected batch.
Outcomes
The primary outcome for this analysis was the diagnosis of ACS. ACS was defined as either AMI occurring during the initial hospital admission (prevalent AMI) or incident major adverse cardiac events (MACE) occurring within 30 days. MACE included death (all cause), incident AMI and urgent coronary revascularization. The diagnosis of AMI was allocated by two independent investigators (blinded for MACS group outcome) in accordance with the third universal definition of AMI [14] based on clinical information and the requirement of patients having a rise and/or fall of hs-cTnT with at least one troponin level above the 99th percentile (14 ng/L). Disagreement (n = 2) was resolved by discussion and were both explained by errors in reading or interpreting hs-cTnT concentrations. Secondary outcomes included the diagnosis of AMI alone and the identification of a new coronary stenosis (N50%) on coronary angiography.
Follow up
All patients were followed up after 30 days, including assessment of (a) the mortality status by using the National Health Strategic Tracing Service (NSTS) database, (b) checking electronic patient hospital records, and (c) personal contact by telephone or in hospital for inpatients. In case patients remained persistently uncontactable their general practitioner (GP) was contacted. Follow up was considered appropriate if the patients GP had been in contact with the patient during the follow up period and was able to provide sufficient information regarding ED attendances, hospital admissions, investigations and episodes of chest pain. In case patients required attention at another hospital in the follow up period, relevant records were obtained in copy from that hospital.
Statistical analysis
Statistical analysis was undertaken using SPSS version 23.0 (SPSS Inc., Chicago, Illinois) and MedCalc version 13.1.2.0 (Mariakerke, Belgium). We summarised baseline characteristics using descriptive statistics.
We applied the previously derived formulae for the MACS and T-MACS models to estimate the probability of ACS, entering cTnI concentrations [4, 5] . Consistent with our approach in the original model derivation, patients with cTnI concentrations below the limit of detection of the assay (6 ng/L) were considered to have concentrations of 5 ng/L. The model classified patients into four distinct risk groups based on their calculated risk probability according to the cut offs applied in the derivation of the original MACS rule. The four risk groups with associated suggestion for patient disposition include: (1) very low risk (p b 0.02; patients eligible for immediate discharge); (2) low risk (0.02 b p b 0.05; suitable for serial cardiac troponin sampling in ED observation ward or comparable alternatives); (3) moderate risk (0.05 b p b 0.95; serial cardiac troponin sampling required in general ward such as Acute Medical Ward); and (4) p N 0.95; ACS considered ruled best managed in a high dependency unit or specialist ward.
Test characteristics including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio and negative likelihood ratio, together with respective 95% confidence intervals (95% CI) were calculated to assess the diagnostic accuracy of the various strategies. Paired comparison of diagnostic accuracy measures was performed with McNemar's test. Additionally, we calculated the area under the receiver operating characteristic (ROC) curves for the MACs and T-MACS rule in conjunction with cTnI, which were compared according to the method described by De Long [15] . Statistical analyses were undertaken using MedCalc, version 17.1 (Mariakerke, Belgium).
Results
We included 405 patients in this study, of whom 66 (16.3%) had AMI and 76 (18.8%) had one or more MACE within 30 days. Patient baseline characteristics are summarised in Table 1 . A participant flow diagram is shown in Fig. 1 Risk stratification of patients over the four distinctive risk groups with MACS and T-MACS is shown in Table 2 . Using the MACS rule with cTnI, 91 patients (22.5%) were categorised as very low risk with no missed ACS or prevalent AMI in this group. Using the contemporary assay with T-MACS increased the number of patients identified as very low risk to 147 (36.3%). One patient (0.7%, 95% CI 0.02-3.8%) developed MACE within 30 days. This patient developed an AMI 8 days after initial presentation to the ED, following which a severe stenosis to the circumflex artery was noted at angiography. This was managed medically without coronary intervention. No prevalent AMIs would have been missed, resulting in 100.0% sensitivity (95%CI 94.6 to 100.0%).
The sensitivity for predicting ACS within 30 days was 100.0% (95% CI: 94.6 to 100.0%) and 98.7% (95% CI 92.9 to 100.0%) for MACS and T-MACS respectively. The absolute difference in sensitivity of 1.32% (95% CI −1.25 to 3.89), p = 1.00 between the two models was not statistically significant. Specificity between the models however differed by 16.72% (95% CI 14.55 to 18.89, p b 0.0001), favouring T-MACS with a specificity of 44.4% (95% CI 38.9 to 49.9) versus 27.7% (95% CI 22.9 to 32.8) for MACS. Both models provided high NPVs for ACS within 30 days with 100% (95% CI 96.0 to 100) and 99.3% (95% CI 96.3 to 100) for MACS and T-MACS, respectively. Additional diagnostic performance characteristics are summarised in Table 3 .
The AUC was 0.943 (95% CI 0.916 to 0.964) for MACS and 0.938 (95% CI 0.909 to 0.959) for T-MACS, resulting in an absolute difference between the areas of 0.005 (95% CI −0.006 to 0.017), p = 0.360. A visual representation is shown in Fig. 2. 
Discussion
In this secondary analysis we have addressed a limitation of the (T-)MACS rule, which had until now only been validated with one assay: hs-cTnT (Roche Diagnostics Elecsys, 5th generation). The contemporary cTnI assay we evaluated in our study meets the precision criteria for being a high-sensitivity troponin assay but cannot quantify troponin levels in N 50% of apparently healthy volunteers [16] . This assay has been shown to provide comparable diagnostic accuracy to highsensitivity assays at the 99th percentile cut-off [17] . The results of our analysis support those earlier findings suggesting that both models, MACS and T-MACS, provide sufficient diagnostic accuracy when used with the cTnI assay for 'ruling out' ACS within 30 days. With the MACS rule the cTnI assay identified 22.5% of patients as eligible for immediate discharge, which is comparable to findings from the two external validation studies using hs-cTnT [7, 9] . With T-MACS the percentage of patients eligible for immediate discharge rises to 36.5% at the cost of missing 1 patient (0.7%) who developed ACS within 30 days. Neither model missed any prevalent AMIs in the very low risk group.
According to a survey study by Than et al. 40% of emergency physicians would be reluctant to discharge a patient if the risk of missing MACE exceeds 1% [18] . Our findings for MACS and T-MACS were within this range but with a clear definition of what risk of missing ACS is generally considered acceptable, decision will remain up to local departmental standards and the risk individual physician are willing to take. Shared decision making might provide an important avenue for further research taking into account patient preferences alongside what clinicians consider acceptable [19] .
MACS and T-MACS both had a diagnostic performance similar to alternative rule out strategies. The HEART score, combining patient history, ECG, age, risk factors and troponin, was mainly validated in studies using contemporary troponin assays, making findings comparable to our analysis. The HEART score was reported with an average sensitivity of 96.7% in a recent meta-analysis and an average of 1.6% (95% CI 1.2-2.0) 'missed' MACE in patients categorised as low risk with a HEART score of 0 to 3 points [20] . Both models in our analysis have reached a similar and even slightly better diagnostic accuracy for ruling out ACS in patients identified as being low risk.
Furthermore, MACS and T-MACS rule have the advantage of providing effective risk stratification of patients not classified as 'very low risk'. The HEART score potentially could be used in a similar fashion but has so far not been evaluated for this aspect. Our analysis demonstrated a high positive predictive value for the patients identified as 'high risk', empowering emergency physicians to not only rule out ACS but providing guidance on patient disposition to high dependency units, increasing the efficient use of the most judicious resources.
Another rule out strategy relying on a single blood test on arrival to the ED in combination with ECG changes, the limit of detection (LoD) rule out, requires the diagnostic precision of high sensitivity troponin assays and therefore is not directly comparable to findings from this analysis. In a recent study evaluating this cTnI assay for ruling out AMI we showed that using the assay at the LoD together with ECG changes was insufficient to rule out prevalent AMI and subsequent MACE [21] .
Other promising strategies usually require some form of serial troponin testing. In a recent derivation and validation study cTnI was shown to potentially rule out AMI with 93.3% sensitivity in a 0/1-hour algorithm and 94.5% sensitivity in a 0/2-hours algorithm in the validation cohort. Patients wrongly classified as 'rule out' usually had ECG changes suggestive of AMI or a previous history of coronary artery disease [22] . The HEART pathway, a modified version of the HEART score relying on Table 3 Diagnostic performance of the MACS and T-MACS models as 'rule out' strategies (i.e. 'very low risk' versus all other risk groups; 95% confidence intervals in parentheses). 0/3-hours serial troponin testing, had 100% sensitivity in a randomized controlled trial with 0% of missed MACE within 30 days [23] , supporting the need to combine cTnI with additional diagnostic features.
Limitations
Our results were limited by the fact that this is a secondary analysis of prospective data, and therefore we did perform a power calculation specifically for this analysis. Nevertheless, the sample size in our analysis should be of acceptable size to answer our objectives and the data, although analysed retrospectively, address the question in a valid fashion. We acknowledge that ideally the cTnI assay should be validated prospectively in clinical practice with both models to support the findings from this analysis. Future research is required to validate the MACS and T-MACS model for additional contemporary and highsensitivity troponin assays commonly used in clinical practice.
Conclusion
Both, MACS and T-MACS when used with the contemporary Siemens Ultra cTnI assay effectively ruled out ACS and risk stratified the remaining patients and therefore could be used in clinical practice. Clinicians need to consider if using T-MACS with cTnI is acceptable to them, considering the higher percentages of patients eligible for discharge at the 0.7% risk of missing ACS within 30 days.
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